Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.50 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.48 |
| ▸ | GRIN2B | Q13224 | 12/20 | 0.48 |
| ▸ | GRIN1 | Q05586 | 9/20 | 0.48 |
| ▸ | BRAF | P15056 | 1/20 | 0.46 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.45 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.45 |
| ▸ | CFTR | P13569 | 1/20 | 0.45 |
| ▸ | RORB | Q92753 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14931902 | 0.89 | PARP1 (0.51) | PARP1PIK3C3GRIN2BGRIN1RORB | |
| SCHEMBL12427702 | 0.86 | CFTR (0.48) | PIK3C3GRIN2BGRIN1HCRTR1HCRTR2 | |
| SCHEMBL4876885 | 0.82 | AXL (0.59) | PIK3C3ALDH1A1 | |
| SCHEMBL1420910 | 0.81 | GRIN2B (0.49) | PARP1GRIN2BGRIN1RORB | |
| SCHEMBL16395600 | 0.80 | KMT2A (0.49) | CFTRALDH1A1 | |
| SCHEMBL1810792 | 0.80 | MAPK1 (0.50) | RORB | |
| SCHEMBL1420861 | 0.79 | GRIN2B (0.50) | PARP1GRIN2BGRIN1 | |
| SCHEMBL1420749 | 0.79 | PARP1 (0.48) | PARP1GRIN2BGRIN1 | |
| SCHEMBL5781938 | 0.78 | NR4A2 (0.54) | HCRTR1HCRTR2CFTRKDM4EALDH1A1 | |
| SCHEMBL1420958 | 0.78 | GRIN2B (0.51) | PARP1GRIN2BGRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461183-B2 | PPAR agonist compounds, preparation and uses | GENFIT (FR) | 2013-06-11 | — | — | US | disclosed |
| EP-2310371-B1 | PPAR AGONIST COMPOUNDS AND PREPARATION AND USES THEREOF FOR TREATING DIABETES AND/OR DYSLIPIDEMIA | GENFIT (FR) | 2013-05-15 | — | — | EP | disclosed |
| US-20110195993-A1 | PPAR AGONIST COMPOUNDS, PREPARATION AND USES | GENFIT (FR) | 2011-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195993-A1 | PPAR AGONIST COMPOUNDS, PREPARATION AND USES | PPARD, PPARA, PPARG | PARP1 2341/4885PIK3C3 4314/4885GRIN2B 2092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.